Test Price
2,800 AED✅ Home Collection Available
DCX Gene Analysis (X-Linked Lissencephaly & Subcortical Band Heterotopia) Genetic Test in UAE | 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing. ✓ Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain and VIP Mobile Phlebotomy. ✓ Clinical Guidance: Telephonic Post-Test Genetic Counseling for result interpretation. ✓ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This NGS-based genetic test targets the DCX gene, the primary cause of X‑linked lissencephaly and subcortical band heterotopia (double cortex syndrome), enabling precise molecular diagnosis, carrier detection, and prenatal risk assessment. The assay employs next-generation sequencing to interrogate all coding exons and flanking intronic regions, with concurrent copy number variant (CNV) analysis to detect large deletions or duplications that Sanger sequencing may miss.
| Feature | Our Test (DCX NGS) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | Full gene sequencing with copy number variant detection | Targeted point mutations only; may miss large deletions/duplications |
| Methodology | NGS (Next Generation Sequencing) – enhanced protocol | Capillary electrophoresis; limited throughput |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics specialist, I emphasize that the DCX gene analysis provides a definitive molecular diagnosis for X-linked lissencephaly and subcortical band heterotopia, yet each result must be contextualized within the full clinical picture including neuroimaging and neurological examination. Carrier females may present with a milder phenotype or remain asymptomatic, making pedigree analysis and genetic counseling essential before and after testing. I encourage patients to engage with reproductive genetics services to explore family planning options and prenatal testing where indicated.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory Notice
Do Not Alter Prescribed Therapy Without Clinical Guidance
Do not discontinue prescribed anticonvulsants, hormones, or any regular medication without consulting your treating physician. Altering therapy solely based on a genetic result can precipitate seizure exacerbation or acute neurological deterioration. Any changes to medication must be managed under direct supervision of a qualified neurologist or epileptologist.
Exclusion Criteria & Emergency Indicators
Pre-Test Requirements & Urgent Warning Signs
- Informed Consent: A legal guardian must provide written informed consent for minors, as mandated by Federal Decree-Law No. 4 of 2016 on Medical Liability. The test will not proceed without documented consent.
- Pedigree Requirement: A complete three-generation family pedigree must be reviewed during a mandatory pre-test genetic counseling session before sample collection is authorized.
- Clinical Instability: Testing is deferred for patients with acute systemic infection requiring hospitalization or those in status epilepticus until stabilized.
- Emergency Red Flag: Sudden onset of severe headache, visual disturbance, prolonged seizure activity, or altered level of consciousness requires immediate emergency department evaluation. These symptoms are not related to the blood draw but may signal acute neurological deterioration that demands urgent medical attention.
Patient FAQ & Clinical Guidance
1. What is the clinical utility of this DCX genetic test?
This test definitively confirms or rules out X-linked lissencephaly and subcortical band heterotopia caused by pathogenic DCX variants, guiding prognosis, tailored antiepileptic therapy, and family planning. It also identifies carrier females who may be asymptomatic but risk transmitting the disorder to sons, enabling informed reproductive choices and prenatal testing in future pregnancies. The NGS methodology detects missense, nonsense, splice-site, and frameshift mutations as well as copy number alterations across the entire DCX coding region.
2. How is the sample collected in the UAE, and is home collection available?
A certified phlebotomist collects a standard venous blood sample (2–5 mL in EDTA tube) or a dried blood spot (FTA card) at your home, office, or our facility between 8 AM and 11 PM daily. The sample is transported under strict ISO 9001:2015 cold-chain protocols directly to our genetic laboratory at DNA Labs UAE in Dubai Healthcare City. VIP Mobile Phlebotomy and temperature-controlled cold-chain home collection are available across all seven emirates with no additional scheduling restrictions beyond the stated hours.
3. What is the turnaround time, and how will I receive my results?
Results are issued within 3 to 4 weeks post-sample collection, delivered via a secure, DHA‑compliant online portal and accompanied by a board‑certified clinical geneticist’s interpretation report. A tele‑consultation is provided to discuss implications for the patient and at-risk family members. Raw sequencing data (BAM and VCF files) can be made available upon request for secondary analysis or future re-interpretation as genomic knowledge evolves.
UAE Regulatory & Data Privacy Adherence
Data Protection & Health Information Governance
All genetic data generated from the DCX gene analysis is stored and processed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient information is encrypted at rest and in transit, with access restricted to authorized laboratory personnel and the referring physician. No genetic data is shared with third parties without explicit written consent from the patient or legal guardian. The laboratory operates under DHA Facility License Number 1143 and adheres to international standards for genetic testing and genomic data stewardship.
Clinical & Logistical Metadata
| Test Name | DCX Gene Analysis (X-Linked Lissencephaly & Subcortical Band Heterotopia) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3-4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) or Dried Blood Spot (FTA Card) |
| Methodology Used | NGS (Next Generation Sequencing) with CNV Analysis |
| ICD-10-CM Code | Q04.3 (Lissencephaly) |
| LOINC Code | 82272-8 (DCX gene mutation analysis in Blood or Tissue by Sequencing) |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians